Provided by Tiger Trade Technology Pte. Ltd.

Tema Heart & Health ETF

35.80
-0.0478-0.13%
Post-market: 35.68-0.1239-0.35%19:30 EDT
Volume:1K
Turnover:45.58K
Market Cap:52.99M
PE:- -
High:35.80
Open:35.68
Low:35.68
Close:35.85
52wk High:38.87
52wk Low:31.64
Shares:1.48M
Float Shares:1.48M
Volume Ratio:0.73
T/O Rate:0.09%
Dividend:0.47
Dividend Rate:1.32%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Judge Denies In Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Judge Denies in Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30